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By engaging Fas, Fas ligand (FasL) on activated T lymphocytes induces activation-induced cell death (AICD), and
also triggers apoptosis of target cells during immune downregulation. We previously showed that within cutaneous
T cell lymphoma (CTCL) lesions, malignant CD4þ T cells expressing FasL accumulated, and were inversely dis-
tributed with CD8þ T cells. We thus determined the responses of human CTCL cells to AICD and their cytotoxic to
Fasþ target T cells in vitro. CTCL cells expressing Fas were resistant to AICD following activation by CD3 mono-
clonal antibody (mAb) whereas still undergoing apoptosis if Fas was ligated to Fas mAb. CTCL cell lines, as well as
Se´zary Syndrome patients’ peripheral blood lymphocytes, exhibited ratio-dependent cytotoxicity to Fasþ Jurkat
cells. The kinetic study showed that FasL surface expression was absent before activation, and its expression was
low and/or delayed after activation. We therefore hypothesize that CTCL cells express functional FasL possibly
contributing to bystander cytotoxicity within tumor inﬁltrates. In addition, decreased and/or delayed FasL surface
expression following activation may in part contribute to their resistance to AICD. Both bystander cytotoxicity and
resistance to AICD are likely to contribute to the loss of cytotoxic anti-tumor CD8þ T cells as well as the ac-
cumulation of malignant T cells in CTCL.
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Cutaneous T cell lymphomas (CTCL) are the most frequent
extra-nodal lymphomas occurring in the skin (Weinstock
and Horm, 1988). Mycosis fungoides (MF), and its leukemic
variant, Se´zary syndrome (SS), the most common CTCL
variants, have been thought to arise from the accumulation
and clonal expansion of skin homing, immunologically ma-
ture, CD4þ /CD45ROþ (helper/memory) T lymphocytes
(Tan et al, 1974). Persistent antigen stimulation, provided by
skin organisms such as viruses and staphylococci, or by
chemicals, has long been hypothesized to serve as the
triggers initiating MF (Tan et al, 1974; Tokura et al, 1994;
Jackow et al, 1997; Herne et al, 2003; Talpur and Duvic,
2003). Disease progress is characterized by increasingly
impaired immunity with a shift to type 2 cytokine profile T-
helper (Th)2, which is hypothesized to result from malignant
T cell accumulation as well as loss of CD8þ tumor-infil-
trating, cytotoxic T lymphocytes (Vowels et al, 1992; Heald
et al, 1994).
Fas ligand (FasL), a type II transmembrane protein that
belongs to the tumor necrosis factor (TNF) family, and its
receptor, Fas (Apo-1/CD95), play an essential role in T cell
homeostasis (Nagata and Golstein, 1995; Bossi and
Griffiths, 1999). FasL was described as a cytotoxic protein
expressed on activated T cells (EL-Khatib et al, 1995). The
primary functions attributed to FasL-mediated cytotoxicity
are the ability of T cells to kill themselves during activation-
induced cell death (AICD) and the ability of T cells to kill
target cells in a calcium-independent manner (Lowin et al,
1996). In AICD-sensitive T cells, FasL expression is upreg-
ulated upon activation, and is delivered to the cell surface.
FasL can then engage Fas on the same (suicide or AICD) or
on a neighboring cell (patricide or bystander cytotoxicity)
(Suda et al, 1995; Bossi and Griffiths, 1999; Green et al,
2003). CTCL cells are populations of activated mature T
cells, which have prolonged life spans, and thus an abnor-
mal cell death; specifically, a defective Fas/FasL pathway
may result in accumulation of CTCL cells (Meech et al,
2001). Decreased Fas expression was found on peripheral
blood CD4þ T lymphocytes in MF and SS (Dereure et al,
2000) and absent Fas expression was associated with more
aggressive CTCL (Zoi-Toli et al, 2000). Because mutations
of the Fas gene were detected in only 14% of CTCL pa-
tients’ tumor cells (Dereure et al, 2002), other abnormalities
linked to Fas/FasL signaling must exist in the pathogenesis
of MF and SS.
Besides its presence on T cells, FasL is expressed on
many other cells from different organs. Expression of FasL
in the eye, placenta, and testis is suggestive of mechanism
for immune privilege (Griffith et al, 1995). FasL can induce
Abbreviations: AICD, activation-induced cell death; CTCL, cuta-
neous T cell lymphoma; FasL, Fas ligand; FITC, fluorescein
isothiocyanate; IL, interleukin; mAb, monoclonal antibody; MF,
mycosis fungoides; MMP, matrix metalloproteinases; PBL, periph-
eral blood lymphocytes; PI, propidium iodide; SS, Se`zary syn-
drome; Th, T helper
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immune cells to undergo apoptosis, and thereby, limit the
immune response in these organs. Tumor cells expressing
FasL have been proposed to ‘‘counterattack’’ against ac-
tivated anti-tumor effector immune cells, although some
authors have indicated that FasL is not expressed on the
surface of some solid tumor cells, such as colon cancer
cells (O’Connell et al, 1996; Favre-Felix et al, 2000). We have
previously shown that within CTCL lesion MF tumor cells
highly express FasL, and were inversely distributed with
CD8þ T cells (Ni et al, 2001); however, the direct evidence
of FasL-mediated bystander cytotoxicity and cell surface
FasL expression on CTCL cells has not been previously
studied.
To better understand the mechanism of abnormal Fas/
FasL pathway in both accumulation of neoplastic Tcells and
loss of immune cytotoxic CD8þ T cells in CTCL, we ex-
amined the susceptibility of human CTCL cells to AICD
through ligation of the CD3/T cell receptor (TCR) as well as
their ability to kill Fasþ T cell targets. We further assessed
the induction of apoptosis following anti-Fas antibody treat-
ment and the kinetics of FasL cell surface expression after
activation. Although CTCL cells kill target cells via Fas/FasL
pathway, they were less susceptible to AICD induced
by anti-CD3 monoclonal antibody (mAb) than to anti-Fas
mAb-induced apoptosis. This difference may be related
to decreased or/and delayed FasL surface expression.
These findings describe a novel mechanism that neoplastic
Tcells may utilize to resist AICD and thus accumulate in skin
lesions.
Results
Resistance to AICD is not correlated with the level of
Fas surface expression ACID is an apoptotic pathway in-
volved in the control of T cell homeostasis (Lenardo, 1997).
We therefore determined the susceptibility to AICD in re-
sponse to CD3/TCR ligation in three CTCL cell lines. Com-
pared with Jurkat cells, HuT78, MJ, and HH cells showed
much less induction of apoptosis after CD3 mAb (2.5 mg per
mL) activation for 16 h. CD3 mAb activation induced an
average 45.1% activation-induced apoptosis of Jurkat
cells, but only 18.2% of HH cells, 6.1% of MJ cells, and
none of HuT78 cells (Fig 1a).
Because AICD is primarily an Fas/FasL-mediated apop-
tosis, we next examined the Fas surface expression by flow
cytometry using the ZB4 mAb. Surprisingly, Fas cell surface
expression was present in all three tested CTCL cell lines
(HuT78¼94.6%; MJ¼97.7%; HH¼86.2%) (Fig 2a, b). Fas
was also expressed on a high percentage (52%–80%) of
CD4þ cells from four Se´zary patients with high percent-
ages of peripheral Se´zary cells (Table I; Fig 2c).
Moreover, as shown in Fig 3, CTCL cells displayed con-
centration-dependent induction of apoptosis when they
were treated with the apoptosis-inducing CH11 Fas mAb,
which mimics the function of physiologic FasL, at different
concentrations (0, 50, and 250 ng per mL). The sensitivity to
CH11 Fas mAb among three CTCL cells was variable. HH
cells showed highest sensitivity, with 41.5% and 54.0%
apoptosis induction at 50 and 250 ng per mL Fas mAb
treatment, respectively, whereas MJ cells just had 2.5% and
15.5%, and HuT78 cells only with 3.6% and 6.6% (Fig 3).
Compared with CD3 mAb activation, three CTCL cell lines
were more sensitive to the treatment of CH11 Fas mAb (250
ng per mL) (Fig 1). Similar to HuT78 cells, all tested SS-
peripheral blood lymphocytes (PBL) displayed resistance to
both CH11 Fas mAb treatment and CD3 mAb-induced AICD
as summarized in Table II. These results suggest that CTCL
cells, especially HuT78 cells and SS-PBL, are resistant to
CD3 mAb-induced AICD although Fas receptor is present
on their surfaces with variable responses to CH11 Fas mAb
treatment.
FasL surface expression is absent on CTCL cells at
baseline Because cell surface FasL expression on activat-
ed T cells is necessary for inducing AICD of Fasþ cells
(Bossi and Griffiths, 1999), using NOK-1 FasL mAb, specific
for cell surface FasL, we next examined FasL expression on
the surface of three CTCL cell lines (HuT78, MJ, and HH)
and PBL from SS patients. As shown in Fig 4, flow cytome-
try (Fig 4a) and confocal microscopy (Fig 4b) showed that
although FasL protein is easily detected on the surface of
control KFL9 cells, surface FasL protein was absent on
three CTCL cell lines (Fig 4a, b), as well as on all tested SS-
PBL at baseline (data not shown).
FasL surface expression is decreased or/and delayed
on CTCL cells after activation Hematopoietic cells store
FasL in secretory lysosomes, which then undergo a polar-
ized delivery to the interface between the effector cell and
its target after activation (Suda et al, 1995; Bossi and
Griffiths, 1999). This delivery of surface FasL occurs within
minutes after activation, reaching the maximum level within
1–2 h with CD3 antibody activation or within 30 min with
phorbol 12-myristate 13-acetate (PMA)/ionomycin activa-
tion (Nguyen and Russell, 2001). In order to study the ki-
netics of cell surface expression of FasL on CTCL cells,
FasL surface expression was determined after activation
with PMA (50 ng per mL)/ionomycin (1 mg per mL) or CD3
mAb (2.5 mg per mL) for 5, 30 min, 3, 16, 24, 48, and 72 h.
Interestingly, cell surface FasL was undetectable after ac-
tivation with either PMA/ionomycin or CD3 mAb for 5, 30
min, 3 and 16 h (data not shown) until 24 h later on HuT78
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Figure1
Cutaneous T cell lymphoma cells are resistant to activation-in-
duced cell death activated by CD3 monoclonal antibody (mAb)
whereas variably responsive to apoptosis-inducing Fas mAb.
HuT78, MJ, HH, and Jurkat cells were activated on 2.5 mg per mL
UCHT-1 CD3 mAb-coated plates (a) or treated with 250 ng per mL
CH11 Fas mAb (b) for 16 h. Apoptosis was measured by staining with
fluorescein isothiocyanate-labeled AnnexinV and propidium iodide
analyzed with a FACScan (Becton Dickinson).
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cells. As shown in Fig 5, FasL cell surface expression on
HuT78 cells was first detectable at 24 h after activation with
CD3 mAb, and continuously increased from 48 to 72 h.
Compared with that at baseline (0.3%), cell surface FasL on
HuT78 cells was 6.3% at 24 h, 6.6% at 48 h, and 14.7% at
72 h, respectively. FasL surface expression on MJ cells was
detectable at 3 h with a low level. But FasL expression on
HH cells was detected at 3 h at a high level, which was
similar to that on Jurkat cells (Fig 5). These data suggest
that different time and amount of FasL expression after ac-
tivation may be associated with their sensitivity to AICD.
CTCL cells mediate bystander cytotoxicity toward Fasþ
target cells To further determine the function of FasL ex-
pressed by CTCL cells, we examined CTCL cells’ cytolytic
activity towards Fasþ target cells. We chose Jurkat T cells
as target cells because they display high sensitivity toward
Fas mAb (Matzinger et al, 1991). As shown in Fig 6a, three
CTCL cell lines displayed target to effector-dependent
cytotoxicity to Jurkat cell targets. HuT78 cells had the high-
est cytotoxicity to Jurkat cells at each target to effector cell
ratio as follows: 9.1% (1:1), 28.1% (1:5), 49.2% (1:10), and
71.6% (1:20), respectively. At ratios 1:10 and 1:20, MJ-in-
duced cell death of 22.4% and 35.2% of Jurkat target cells.
HH cells were least cytotoxic, killing only 10.3% of Jurkat
cells at the ratio of 1:20 (Fig 6a).
As shown in Fig 6, in Hut78 cells, we were able to block
cytotoxicity by pretreating Hut78 cells with neutralizing
Figure 2
Fas is constitutively expressed on cutaneous T cell lymphoma (CTCL) cells and CD4þ peripheral blood lymphocytes (PBL) from patients
with Se´zary syndrome. (a) Flow cytometric analysis was performed on CTCL cell lines, Jurkat cells, and KFL9 cells labeled with ZB4 monoclonal
antibody (mAb) (green lines) in a suspension. An isotype-matching IgG1 was stained as a negative control (gray filled lines). A total of 10,000 events
were analyzed for each sample. (b) Confocal microscopic analysis was performed after cytospinning cells on silanated glass slides. Three cells
(KFL9 and HH cells) and five cells (HuT78 and MJ cells) were photographed using an Olympus FV500 Confocal Microscope under  60 mag-
nifications. Upper panel: IgG1 staining. Lower panel: ZB4 mAb staining. Scale bar: 10 mm. (c) Flow cytometric analysis was performed on PBL from
patients with a high percentage of circulating CD4þCD26 cells using ZB4 mAb and CD4 mAb co-labeled. The isotype-matching IgG were used as
negative controls. Data are results from patients 3 and 4.
Table I. Demographics and immunophenotyping characteristics of Se´zary Syndrome patients
Patient
no. Age/sex
Disease
stage
CD3þ /CD4þ
cells (%)
CD3þ /CD8þ
T cells (%)
CD4:CD8
ratio
CD4þ /CD26
T cells (%)
Fasþ /CD4þ
T cells (%)
1 50/M IVA 89.9 2.8 32.1 88.7 N/A
92.1 2.3 40.0 92.1 80.1
2 74/M IVB 81.6 6.2 13.2 80.3 52.3
3 66/F IVA 96.0 1.6 60.0 93.3 63.2
4 63/M IVA 87.3 2.3 37.9 80.7 73.8
M, male; F, female; N/A, not applicable.
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antibody to FasL (NOK-2) (Fig 6b) or inhibit the cytotoxicity
by pretreating Jurkat cells with antagonistic antibody to Fas
(ZB4) (Fig 6c) in a coculture containing Jurkat cells to Hut78
cells of 1:10. These data indicate that FasL expressed by
CTCL is functional.
As shown in Fig 6d, target Jurkat cells were cocultured
with PBL isolated from patients with SS-PBL and were
compared with PBL from the normal donors (N-PBL). SS-
PBL from all five samples derived from four different pa-
tients had higher cytotoxicity towards target Jurkat cells
than did control N-PBL. The cytotoxicity was also increased
as the ratio of target cells to effectors increased from 1:1,
1:5, 1:10, to 1:20 (two-sample t test with unequal variance
provides 79%, 92%, 95%, and 93% power to detect
the differences at a significance level of 0.05 (two sided),
respectively).
Discussion
The Fas/FasL pathway may play a dual role in CTCL by
allowing the accumulation of neoplastic CD4þ T cells as
well as by facilitating the loss of CD8þ cytotoxic T cells.
Thus, we were interested in learning how the Fas/FasL
machinery functions in CTCL cells. In this study, three
human CTCL cell lines and SS-PBL were analyzed for their
Figure 3
Sensitivity to anti-Fas-inducing apoptosis varies among cutaneous T cell lymphoma cell lines. (a) HuT78, MJ, HH, and Jurkat cells were
incubated with different concentrations (0, 50, and 250 ng per mL) of apoptosis-inducing CH11 Fas monoclonal antibody (mAb) for 16 h. Apoptosis
was measured by staining with fluorescein isothiocyanate (FITC)-labeled AnnexinV/(propidium iodide (PI)) analyzed with a FACScan (Becton
Dickinson). The percentages of early apoptotic cells (stained only AnnexinV) and late apoptotic cells (stained both AnnexinV and PI) are shown in the
diagrams. (b) Bar graph of data for each cell line at different mAb dose levels.
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responses to Fas mAb treatment and AICD mediated by
CD3/TCR ligation. FasL cytotoxic activity of CTCL cells to-
wards Fasþ Jurkat target cells was also evaluated and by-
stander cytotoxicity to Fasþ target cells was demonstrat-
ed. Differences in susceptibility to Fas mAb and resistance
to AICD were found among CTCL cell lines. Surprisingly,
resistance to AICD in CTCL cells was not because of lack of
expression of Fas on the cells, but perhaps rather to de-
creased or/and delayed FasL surface expression. These
findings describe a possible novel mechanism that neo-
plastic T cells may utilize to resist AICD and over expand.
Normal naı¨ve CD4þ T cells proliferate in response to
superantigens or peptides on antigen-presenting cells.
When these cells are rested and rechallenged, they under-
go AICD mediated by Fas/FasL interactions (Wang et al,
1997). Neoplastic T cells from CTCL patients are considered
as a population of ‘‘genotraumatic’’ CD4þ T cells activated
by unknown persistent antigens (Thestrup and Kaltot, 1994;
De Panfilis, 2002). If the Fas/FasL-mediated pathway is ei-
ther lacking or altered in CTCL cells, they would be unable
to undergo AICD and would accumulate causing clinical
symptoms and lesions (Dereure et al, 2000; Zoi-Toli et al,
2000; Ni et al, 2001; De Panfilis, 2002). Fas mutations are
infrequent in early MF (Dereure, 2002). We found that a
comparable expression of Fas is present at all tested CTCL
cells, but the sensitivity to CD95 and AICD varies among
these cells. This suggest that a normal expression of Fas
does not exclude the possibility of a functional impairment
of the molecule, i.e., abnormal ligand or through modifica-
tion of its intracellular part interacting with the connecting
molecules involved in cell death triggering.
Expression of FasL on cell surface has been thought to
be required during a crucial period after activation in order
for T cells to commit to AICD (Nguyen and Russell, 2001). In
normal CD4þ T cells, FasL appears on the cell surface
within minutes after activation, and membrane-bound or
cleaved FasL molecules bind to Fas receptors on the
surface of the same or on a neighboring cell to trigger the
death cascade (Bossi and Griffiths, 1999; De Panfilis, 2002).
Our study has showed that CTCL cells are resistant to
Figure 4
No Fas ligand (FasL) surface expression on cutaneous T cell lymphoma (CTCL) cells at baseline. (a) Flow cytometric analysis was performed
on CTCL cell lines and KFL9 cells labeled with NOK1 mAb (green lines) in a suspension. An isotype-matching IgG1 was stained as a negative
control (gray filled lines). (b) Confocal microscopic analysis was performed after cytospinning cells on silanated glass slides. Two cells (KFL9 and HH
cells) and five cells (HuT78 and MJ cells) were photographed using an Olympus FV500 Confocal Microscope under  60 magnifications. Scale bar:
10 mm.
Table II. CH11 Fas mAb-induced apoptosis and CD3 mAb-induced AICD in PBL from patients with Se´zary syndrome
Annexin Vþ /PIþ
apoptotic cells (%)
Bexarotene
(20 lm per mL)
Fas mAb (CH11) (ng per mL)
AICD
(2.5 lg per mL)50 250 500
Patient 1 32.6 0.5 0.7 1.8 2.9
Patient 2 12.3 1.4 8.5 10.1 6.3
Patient 3 8.8 0.3 5.0 8.0 13.5
Patient 4 9.1 1.3 2.9 6.6 5.6
mAb, monoclonal antibody; AICD, activation-induced cell death; PBL, peripheral blood lymphocytes.
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activation-induced apoptosis. In addition, we are first to
demonstrate that FasL surface expression is absent at
baseline and deceased or/and delayed following activation
in those resistant cells, HuT78, and MJ cells. Thus, CTCL
cells may resist AICD because of a decreased or/and de-
layed in the expression of a critical amount of FasL on their
cell surface. Others have demonstrated that most FasL ex-
pressed by activated T cells is located into cytoplasmic
granules, together with perforin and granzyme. The interac-
tion between effector and target cell is associated with po-
larization of granules toward the cell–cell interface, followed
by release of FasL and granules into the intercellular space
(Bossi and Griffiths, 1999). Thus, we propose a working
hypothesis that by granule release, a CTCL cell may be able
to kill a target cell using a FasL-dependent mechanism, in
the absence of detectable FasL protein surface expression.
Interestingly, a study has found that the lack of interleukin
(IL)-2, which is common in SS patients, possibly delayed the
expression of FasL so that it was not expressed during the
crucial period (Nguyen and Russell, 2001). But the results
from the cell lines may or may not reflect the actual behavior
in vivo; more ex vivo or in vivo studies need to be carried out
in the future to test this hypothesis.
During T cell development, CD4þ Th cells differentiate
in response to antigen stimulation into Th1 or Th2 cells,
defined by their cytokine expression pattern. Th1 cells pro-
duce IFN-g, TNF-a, and IL-2 that are important for the cell-
mediated immune response against intracellular pathogens.
Th2 cells produce IL-4, IL-5, IL-6, and IL-10, which are in-
volved in humoral immunity (Li-Weber and Krammer, 2002).
As mentioned above, after encountering either a superan-
tigen or a specific antigen, the majority of activated T cells
are deleted by AICD. Many studies have, however, shown
that deletion is never complete (Carbonari et al, 2000). Re-
sidual undeleted cells after activation express high levels of
Th2-type cytokines, indicating that Th2 cells are resistant to
AICD (Carbonari et al, 2000; Dirsch et al, 2001). Although
the aberrant cytokine production by Se`zary cells resembles
that of murine Th2 cells, the mechanism(s) leading to the
dominance of type-2 responses of these cells has not been
clarified (Vowels et al, 1992, 1994). Our study has demon-
strated that in spite of different sensitivity to anti-Fas mAb-
induced apoptosis, all three CTCL cell lines were resistant
to AICD triggered by CD3 mAb. We hypothesize that AICD
resistant, Th2 CTCL cells are able to survive an immune
response followed by AICD and to contribute to the pool of
Figure 5
Decreased or/and delayed cell surface Fas ligand (FasL) induction in cutaneous T cell lymphoma (CTCL) cells after CD3 monoclonal
antibody (mAb) activation. HuT78, MJ, HH, and Jurkat cells were activated on UTCH-1CD3 mAb-coated plate for different times (3, 16, 24, 48, and
72 h). Cells from baseline and different activation time points were then labeled with NOK-1 mAb (empty lines) in a suspension analyzed with a
FACScan. The isotype-matched IgG1 was used as negative control (gray filled lines).
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long-term helper/memory T cells. Other studies have also
shown significant differences in the level of FasL surface
expression induced in AICD-susceptible Th1 cells, but not
in AICD-resistant clone Th2 cells (Oberg et al, 1997;
Varadhachary et al, 1997). The molecular basis for the dif-
ferential expression of FasL in Th1 and Th2 cells is un-
known. Li-Weber and Krammer (2002) have reported that
NF-AT and early growth response protein seems to play a
major role in FasL expression upon TCR stimulation.
The regulatory mechanism for FasL surface expression is
not fully understood. Because Fas is a death-inducing re-
ceptor and FasL must be tightly controlled at different lev-
els, these may include delivery to the cell surface, cytokine
release, as well as cell membrane-associated matrix met-
alloproteinases (MMP). FasL is cleaved from the cell surface
by several members of the MMP family (Kayagaki et al,
1995; Webb et al, 2002). Treatment of activated T cells or
tumor cell lines with MMP inhibitors in vitro leads to the
accumulation of surface FasL (Strauss et al, 2003). Treat-
ment of all three of CTCL cell lines used in the study with a
potent broad-spectrum MMP inhibitor had little effect on the
level of FasL on the cell surface (not shown). This result is
consistent with Nguyen and Russell’s (2001) observation
that MMP inhibitors have little effect on the loss of FasL in
T cells, but that downregulation of FasL is because of
endocytosis.
In CTCL, loss of the cytotoxic CD8þ T cells is correlated
with disease progression and loss of response to photo-
pheresis (Heald et al, 1992). Tumors can escape from im-
mune surveillance by expressing FasL on their surface and
thus causing bystander apoptosis of Fasþ infiltrating T
cells (Green and Ferguson, 2001; Li et al, 2002; Abrahams
et al, 2003). Our work has previously shown that tumor cells
in MF skin lesions express FasL, with an inverse correlation
between distribution of FasL and CD8þ T lymphocytes (Ni
et al, 2001). This study conducted on cells in vitro suggests
that CTCL cell lines and SS cells from patients are capable
of inducing bystander cytotoxicity of Fasþ T target cells. Of
interest, HuT78 cells, an SS cell line, showed greatest cyto-
toxicity and were most resistant to AICD whereas the most
sensitive lymphoma cell line HH has the lowest cytotoxic
activity against Jurkat cells. In SS, there is a significant in-
crease in circulating activated abnormal CD4þ T cells
leading to leukemia. FasL-medicated bystander cytotoxic
activity by neoplastic CTCL cells could clearly contribute to
loss of CD8þ T cells seen in SS and MF patients as the
disease progresses.
Of interest, all-trans retinoic acid had recently been
shown to reduce surface expression of Fas and FasL on
acute promyelocytic leukemia cells in vitro and to decrease
their ability to induce apoptosis of Jurkat T cells (Salih et al,
2002). Learning how to best protect the anti-tumor cytotoxic
Figure 6
Fas ligand (FasL)-mediated
bystander cytotoxicity by cuta-
neous T cell lymphoma (CTCL)
cells. (a) Jurkat cells (2  104
cells per mL) labeled with [3H]-
thymidine were co-cultured with
HuT78 (-~-), MJ (-’-), or HH
cells (-m-) at 2  104, 1  105,
2  105, and 4  105 per mL in
96-well plates for 24 h at 371C.
The incorporated radioactivity
from undegraded chromosomal
DNA of Jurkat cells was meas-
ured. Reduction in incorporated
radioactivity was used to calcu-
late the percentage of specific
target cell killing: ((cpm untreated
cells-cpm cocultured cells)/cpm
untreated cells  100). Treatment
of Jurkat cells with 0.25 mg per
mL of death-inducing CH11 mAb
served as a positive control (--).
The negative control for sponta-
neous cell death was wells con-
taining only Jurkat cells without
effector cells (-x-). (b) Specific
killing of target cells was blocked
when HuT78 cells were incubated
with 2.5 mg per mL of NOK-2 FasL
mAb before coculture with labe-
led Jurkat cells, but not with a
relevant negative control IgG2a
mAb. (c) The specific killing of
Jurkat cells was inhibited when
Jurkat cells were incubated with
0.25 mg per mL of the Fas recep-
tor blocking ZB4 mAb before
co-culture with HuT78 cells, but not with a relevant negative control IgM mAb. (d) Jurkat cells labeled with [3H]-thymidine were co-cultured with
peripheral blood lymphocytes (PBL) from patients with high circulating Se´zary syndrome (SS) cells (SS-PBL) and normal donors (N-PBL) at the ratios
of target cells to effector cells of 1:1; 1:5; 1:10; 1:20. The incorporated radioactivity from Jurkat cell DNA was also measured and the specific target
killing (%) was presented.
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CD8þ T cells in the tumor microenvironment would cer-
tainly advance therapeutic strategies for CTCL patients.
Materials and Methods
Established cell lines Three CTCL cell lines (HuT78, MJ, and HH)
with an immunophenotype CD3þ , CD4þ , and/or CD25þ were
obtained from American Type Cell Collection (Rockville, Maryland).
HuT78 cell line was established from a patient with SS (ATCC
number: TIB-161). The MJ cell line was from a patient with MF who
was HTLV-1 positive (ATCC number: CRL-8294). The HH cell line
was derived from a patient with aggressive cutaneous T cell le-
ukemia/lymphoma (ATCC number: CRL-2105). These cell lines
have been shown to express FasL by immunocytochemistry and
ELISA (Ni et al, 2001). Jurkat T cells (1G5, McKesson HBOC Bio-
sciences, Rockville, Maryland, Cat. Number: 1819) expressing Fas
were used as the target in the FasL function assay, and were from
Drs E. Aguilar-Cordora and J. Belmont (Baylor College of Medicine,
Houston, Texas). The KFL9 cell line, a human FasL transfectant of
human myeloid leukemia K562 cells, was a gift from Dr D. Kaplan
(Cleveland, Ohio) (Smith et al, 1998). All cell lines were cultured in
RPMI-1640 medium supplemented with 10% fetal bovine serum
and antibiotics.
PBL from patients with SS The institutional review board of Uni-
versity of Texas, M. D. Anderson Cancer Center approved all de-
scribed studies. Experiments performed adhered to Declaration of
Helsinki guidelines. Following written consent, venous blood was
collected from normal donors and four untreated patients with SS
(shown in Table I). These patients had a high percentage of cir-
culating CD4þCD26 cells that have been shown in two studies
to correlate with peripheral Se´zary cells (Bernengo et al, 2001;
Washington et al, 2002). From patient 1, two samples with different
percentage of CD4þCD26 T cells were obtained at baseline and
5 mo later. Peripheral blood mononuclear cells were separated by
Histopaque-1077 density gradient centrifugation (Sigma, St Louis,
Missouri). After removing adhesive monocytes by incubation at
371C for 1 h, PBL were used for the FasL function assay and
immunophenotyping.
Antibodies and reagents For the FasL function assay, we used
the following antibodies: mouse anti-human FasL mAb, clone
NOK-2 (BD Biosciences, San Diego, California), mouse anti-human
Fas mAb, clone CH11 and ZB4 (Kamiya, Thousand Oaks, Califor-
nia), and isotype-matched controls IgG2a and IgM (DakoCytomat-
ion, Carpinteria, California). For the FasL and Fas cell surface
expression, we used mouse anti-human FasL mAb, clone NOK-1
(BD Biosciences), and mouse anti-human Fas mAb, clone ZB4 as
primary antibody, and fluorescein isothiocyanate (FITC)-conjugat-
ed F(ab0)2 fragment of rabbit anti-mouse immunoglobubins
(DakoCytomation) as secondary antibody. For the characterization
of immunophenotype of PBL, phycoerythrin (PE)-conjugated
mouse anti-human CD4 mAb, clone RPA-T4, and the isotype con-
trol, PE-conjugated IgG1,k were used (BD Biosciences). For T cell
activation, mouse anti-human CD3 mAb, clone UCHT-1 (IgG1,k,
DakoCytomation), PMA, and ionomycin (Sigma) were used.
For induction of apoptosis, bexarotene {LGD1069; 4-[1-(3, 5, 5,
8, 8-pentamethyl-5, 6, 7, 8-terahydro-2-naphthyl) ethenyl]
benzoic acid} (Ligand Pharmaceuticals, San Diego, California)
(Zhang et al, 2002).
Measurement of AICD CD3 mAb (2.5 mg per mL) was coated to
24-well plates for 1 h at 371C. The wells were rinsed thoroughly
prior to addition of 2  105 per well of HuT78, MJ, HH, and Jurkat
cells in triplicate. After incubation for 16 h, AnnexinV-FITC/prop-
idium iodide (PI) staining was performed according to the manu-
facturer’s instruction (AnnexinV-FITC Apoptosis Detection Kit, BD
Biosciences). Briefly, cells were collected, and suspended in 100 ml
Annexin V binding buffer; FITC-conjugated AnnexinV and PI were
added to each sample and incubated for 15 min at room temper-
ature in the dark. After adding 400 mL of binding buffer, the cells
were analyzed by flow cytometry. Experiments were repeated
twice. The level of AICD (%) was calculated as: ((% death with
activation% death without activation)/(100% death without
activation).
Measurements of FasL and Fas by ﬂow cytometry analysis
FasL and Fas cell surface expression on CTCL cells KFL9, HuT78,
MJ, HH, and Jurkat cells were first incubated with NOK-1 FasL
mAb or ZB4 Fas mAb, both at 10 mg per mL on ice for 30 min.
FITC-conjugated secondary Ab (1:20) was then added and incu-
bated on ice for 30 min. Following washing, the cells were analyzed
by flow cytometry (FACScan; Becton Dickinson, San Jose, Cali-
fornia). Isotype-matched IgG1 and only secondary Ab were used
as negative controls.
FasL and Fas cell surface expression on CD4þ PBL PBL from SS
patients were first incubated with NOK-1 FasL mAb, or ZB4 Fas
mAb followed by FITC-conjugated secondary Ab incubation as
described above. Then, PE-conjugated CD4 mAb was incubated
on ice for 30 min. The dual-labeled cells were analyzed by flow
cytometry. Isotype-matched IgG1 and PE-IgG1,k were used as the
negative controls, respectively.
Measurement of FasL and Fas by confocal microscopic anal-
ysis Non-permealized HuT78, MJ, HH, and KFL9 cells were in-
cubated with NOK-1 FasL mAb or ZB4 Fas mAb for 45 min on ice,
and followed by second anti-mouse FITC-conjugated Ab incuba-
tion for 45 min on ice. Cells were then fixed in 1% paraformalde-
hyde and cytospinned onto silanated glass slides, and analyzed
with an Olympus FV500 Confocal Microscope (Olympus American,
Melville, New York). An isotype-matched IgG1 was used as a neg-
ative staining control.
Fas mAb-induced apoptosis by CH11 antibody CTCL cell lines
and Jurkat cells (1  106 per mL) were plated in 12-well plates.
CH11 Fas mAb was added at concentrations of 0, 50, or 250 ng per
mL and incubated for 16 h at 371C. Annexin V-FITC/PI staining was
performed as above. Each data point was performed in triplicate.
FasL-mediated bystander cytotoxicity assay Target Jurkat cells
were co-cultured with effector CTCL cells and cytotoxicity was
measured by target cell DNA degradation using the JAM test
(Matzinger, 1991; O’Connell et al, 1996; Villunger et al, 1997).
Briefly, Jurkat cells incubated with 10 mCi per mL [3H]-thymidine
(Amersham, Buckinghamshire, UK) for 5 h were re-suspended at
2  104 cells per mL. CTCL cells serially diluted to concentrations
of 4  105, 2  105, 1  105, and 2  104 per mL in 100 mL aliquots
were co-cultured with 100 mL of Jurkat T cell suspensions in 96-
well plates for 24 h at 371C. The final target cell (T) to effector cell
(E) ratios were 1:20, 1:10, 1:5, and 1:1. Cells were then harvested
and transferred to filter paper. After washing, the incorporated ra-
dioactivity from intact chromosomal DNA retained on filters was
measured with the b-scintillation counter. Reduction in incorporat-
ed radioactivity was used to calculate the percentage of specific
target cell killing ((cpm untreated cellscpm cocultured cells)/cpm
untreated cells  100). For the FasL neutralizing control, CTCL
cells were incubated with 2.5 mg per mL of anti-FasL mAb (NOK-2)
or with a relevant negative control IgG2a mAb, respectively, 30 min
before co-cultivation with labeled Jurkat cells. For the Fas agonist
control, labeled Jurkat cells were incubated with 0.25 mg per mL of
the Fas receptor blocking ZB4 mAb or a relevant negative control
IgM mAb, respectively, 30 min before co-cultivation with CTCL
cells. Treatment of labeled Jurkat cells with 0.25 mg per mL of
death-inducing anti-Fas mAb, clone CH11, served as a positive
control for Fas-mediated apoptosis. The negative controls for
spontaneous cell death were wells containing only Jurkat cells
without effector cells. The cytotoxicity of Jurkat cells towards
CTCL cells was also performed using [3H]-thymidine-labeled CTCL
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cells exposed to unlabeled Jurkat cells at the same effector cell/
target cell (E/T) ratios. All experiments were performed in triplicate.
Statistics Statistical significance of results was determined by
w2 test and t test. Differences between experimental groups were
considered significant at po0.05.
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